Non-HIV antivirals - A review of the recent patent literature

IDrugs

Volumn 5, Issue 8, 2002, Pages 815-827

  Combrink, Keith ^a  

^a Cumbre Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; AG 6084; ALPHA INTERFERON; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BORONIC ACID DERIVATIVE; CIDOFOVIR; CLEVUDINE; CONSENSUS INTERFERON; FAMCICLOVIR; FOSCARNET; GANCICLOVIR; ICN 3142; IMIDAZOLINE DERIVATIVE; LAMIVUDINE; MERIMEPODIB; NUCLEOSIDE ANALOG; PALIVIZUMAB; PEGINTERFERON ALPHA2B; PEPTIDE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; QUINOLINE DERIVATIVE; REBETROL; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAMIDINE; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; RUPINTRIVIR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR;

ANEMIA; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CYTOMEGALOVIRUS; IC 50; IN VIVO STUDY; NONHUMAN; PICORNAVIRUS; RECURRENT INFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SIDE EFFECT; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; WART VIRUS;

EID: 1642513617     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Davis GL: Current therapy for chronic hepatitis C. Gastroenterology (2000) 118:S104-S114.
2. Patel K, McHutchison J: Peginterferon α-2b: A new approach to improving response in hepatitis C patients. Exp Opin Pharmacother (2001): 2:1307-1315.
3. Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S, Clement RP: A dose-ranging study of PEGylated interferon alfa-2B and ribavirin in chronic hepatitis C. Hepatology (2000): 32:647-653. This study claims an increase in response rate with PEG-IFN that is partly due to the use of more patients with non-type 1 infection in the high dose groups. Dose-related anemia is observed with ribavirin.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: PEGinterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet (2001) 358:958-965.
5. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med (1998) 339:1495-1492.
6. Li Iacono O, Castro A, Diago M, Moreno JA, Fernandez-Bermejo M, Vega P, Garcia V, Carbonell P, Sanz P, Borque MJ, Garcia-Bueyl L et al. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy. Aliment Pharmacol Ther (2000) 14:463-469.
7. WietzkeBetaraun P, Meier V, Braun F, Ramadori G: Combination of "low-dose" ribavirin and interferoon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy. World J Gastroenterol (2001) 7:222-227.
8. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling M-H, Albrecht J: Interferon Alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med (1998) 339:1493-1499.
9. 2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. J Viral Hepatitis (2000) 7:403-408. Data from this study clearly that non-responders do not benefit from the addition of ribavirin, while relapse patients do show an increased response rate in some cases.
10. 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection. Z Gastroenterol (2001) 39:199-206. This study found much lower response rates for both relapse patients and non-responders in an unbiased European population.
11. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB: Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology (1997) 26:473-477. The results of this study demonstrate that ribavirin has no significant impact on the HCV virus titer, but a reduction of ALT and hemoglobin levels are observed.
12. Zeuzem S, Schmidt JM, Lee JH, von Wagner M, Teuber G, Roth WK: Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover. Hepatology (1998) 28:245-252. This paper reports that tibavirin has little effect on viral load, suggesting that the mode of action is unrelated to antiviral activity.
13. Snell NJ: Ribavirin - Current status of a broad spectrum antiviral agent. Exo Opin Pharmacother (2001): 2:1317-1324.
14. Bergamini A, Bolacchi F, Cerasari G, Carvelli C, Faggioli E, Capparulo M, Demin F, Uccella I, Bongiovanni B, Niutta P, Capozzi M et al. Lack of evidence for the TH2 predominance in patients with chronic hepatitis C. Clin Exp Immunol (2001) 123:451-458.
15. Hong Z, Ingravallo P, Cretton-Scott E, Xie M, Zhong W, Baroudy B, Sommadossi J-P, Lau J: Inhibition of host inosine monophosphate dehydrogenase (IMPDH) as an anti-HCV therapeutic approach. Hepatology (1999) 30(4 Pt 2):408A. This abstract claims the antiviral effect of ribavirin is unrelated to IMPHD inhibition.
16. Markland W, McQuaid TJ, Jain J, Kwong AD: Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitory VX-497: A comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob Agents Chemother (2000): 44:859-866. VX-497 demonstrates antiviral activity against polio virus in cell culture, and the report claims that the antiviral effect is due to IMPDH inhibition.
17. Beaulieu PL, Llinas-Brunet M: Therapies for hepatitis C infection: Targeting the non-structural proteins of HCV. Curr Med Chem Anti-infective Agents (2002): 1:163-176. A comprehensive review of progress in the design of inhibitors of the non-structural proteins of HCV.
18. Bartenschlager R, Ahlborn-Laake L, Yasargil K, Mous J, Jacobsen H: Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J Virol (1995) 69:198-205.
19. Llinas-Brunet M, Bailey M, Fazal G, Ghiro E, Gorys V, Goulet S, Halmos T, Maurice R, Poirier M, Poupart MA, Rancourt J et al. High potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: Towards smaller inhibitors. Bioorg Med Chem Lett (2000) 10:2267-2270. These compounds are the smallest and most potent NS3 inhibitors reported to date.
20. Poupart M-A, Cameron DR, Chabot C, Ghiro E, Goudreau N, Goulet S, Poirier M, Tsantrizos YS: Solid-phase synthesis of peptidomimetic inhibitors for the hepatitis C virus NS3 protease. J Org Chem (2001) 66:4743-4751.
21. Schecter I, Berger A: On the size of the active site in proteases. Biochem Biophys Res Comun (1967) 27:157-162. The numbering for the cleavage site starts at the sissile bond and increases toward the amino terminus, and the prime site residues extended to the carboxy terminus. The nomenclature used for describing amino acid residues in the substrate (P2, P1, P1′, P2′, etc) and the corresponding enzyme subsites (S2, S1, S1′, S2′, etc) is described.
22. Zhang R. Durkin JP, Windsor WT: Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease. Bioorg Med Chem Lett (2002) 12:1005-1008.
23. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development. Adv Drug Deliv Rev (1997) 46:3-26.
24. Tyndall JD, Fairlie DP: Macrocycles mimic the extended peptide conformation recognized by aspartic, serine, cyteine and metalloproteases. Curr Med Chem (2001) 8:893-907.
25. Fairlie DP, Abbenante G, March DR: Macrocyclic peptidomimetics - Forcing peptides into bioactive conformations. Curr Med Chem (1995) 2:654-686.
26. Venkatraman S, Njoroge FG, Girijavallabhan V, McPhail AT: Application of ruthenium-induced macrocyclization for the construction of macrocyclic depsipeptides. J Org Chem (2002) 67:3152:3155.
27. Arasappan A, Chen KX, Njoroge FG, Parekh TN, Girijavallabhan V: Novel dipeptide macrocycles from 4-oxo, -thio, and -amino-substituted proline derivatives. J Org Chem (2002) 67:3923-3926.
28. Ingallinella P, Fattori D, Altamura S, Steinkuehler C, Koch U, Cicero D, Bazzo R, Cortese R, Bianchi E, Pessi A: Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus. Biochemistry (2002) 41:5483-5492.
29. Sintchak MD, Nimmesgern E: The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology (2000) 47:163-184.
30. Wright T, Shiffman ML, Knox S, Ette D, Kaufmann RS, Alan J: Dose-ranging study of VX-497, a novel oral IMPDH inhibitor, in patients with hepatitis C. Hepatology 30:Abs 990. VX-497 lowered ALT levels but no effect on viral load at all doses tested.
31. Yuen MF, Lai CL: Treatment of chronic hepatitis B. Lancet Infect Dis (2001) 1:232-241.
32. Bryant ML, Bridges EG, Placidi L, Faraq A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, Juodawlkis A et al.: Anti-HBV specific β-L-2′-deoxynucleosides. Nucleosides Nucleotides Nucleic Acids (2001) 20:597-607.
33. Cretton-Scott E, Bridges EG, Zhou X-J, Juodawlkis A, Gosselin G, Imbach J-L, Pierra C, Benzaria S, Sommadossi J-P, Bryant M: Pharmacokinetics of β-L-2′-deoxycytidine prodrugs in monkeys. Antiviral Res (2001) 50:Abs 16.
34. Alford CA, Britt WJ: Cytomegalovirus. In: Virology, 2nd Edition. Fields BN, Knipe DM (Eds) Raven Press Ltd, New York, NY, USA (1990).
35. Schmidt AC, Couch RB, Galasso GJ, Hayden FG, Mills J, Murphy BR, Chanock RM: Current research on respiratory viral infections: Third international symposium. Antiviral Res (2001) 50:157-196.
36. Krilov LR: Recent developments in the treatment and prevention of respiratory syncytial virus infection. Exp Opin Ther Pat (2002) 12:441-449.
37. Cordingly MG, Callahan PL, Sardana VV, Garsky VM, ColonnoRJ: Substrate requirements of Human rhinovirus 3C protease for peptide cleavage in vitro. J Biol Chem (1990) 265:9062-9065.
38. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R et al.: Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc Natl Acad Sci USA (1999) 96:11000-11007.
39. Gall SA: Female genital wards: Global trends and treatments. Infect Dis Obstet Gynecol (2001) 9:149-154.
40. Cheah PL, Looi LM: Biology and pathological associations of the human papillomavirus: A review. Malays J Pathol (1998) 20:1-10.
41. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 189:12-19.
42. Boehringer Ingelheim (Canada) Ltd (Llinas-Brunet M, Bailey MD, Cameron D, Ghiro E, Goudreau N, Poupart M-A, Rancourt J, Tsantrizos YS, Faucher A-M, Halmos T, Wernic DM, Simoneau B): Hepatitis C inhibitor tripeptides. US-06323180 (2001).
43. Schering Corp (Saksena AK, Girijavallabhan VM, Saksena AK, Girijavallabhan VM, Bogen SL, Lovey RG, Jao EE, Bennett F, McCormick JL, Wang H, Pike RE): Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. WO-00208187 (2002).
44. DuPont Pharmaceuticals Co (Han W): α-Ketoamide inhibitors of hepatitis C NS3 protease. WO-00140262 (2001).
45. Schering Corp (Zhang R): Azapeptides useful in the treatment of hepatitis C. WO-00158929 (2001).
46. Corvas International Inc (Lim-Wilby M, Levy OE, Brunck TK): Novel peptides useful as inhibitors of hepatitis C virus NS3 serine protease. WO-00208251 (2002).
47. DuPont Pharmaceuticals Co (Kettner CA, Jagannathan S, Forsyth TP): Peptide boronic acid inhibitors of hepatitis C virus protease. WO-00102424 (2001).
48. Vertex Pharmaceuticals Inc (Perni R, Court J, O'Malley E, Bhisetti GR): Inhibitors of serine proteases particularly hepatitis C virus NS3 protease. WO-00174768 (2001).
49. Schering Corp (Saksena AK, Girijavallabhan VM, Lovey RG, Jao EE, Bennett F, McCormick JL, Wang H, Pike RE, Bogen SL, Chan T-Y, Liu Y-T et al.): Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. WO-00208244 (2002).
50. Eli Lilly & Co Inc (Babine RE, Chen SH, Lamar JE, Snyder NJ, Sun XD, Tebbe MJ, Victor F, Wang QM, Yip YYM, Collado I, Garcia-Paredes C et al.): Peptidomimetic protease inhibitors. WO-00218369 (2002).
51. Schering Corp (Saksena AK, Girijavallabhan VM, Lovey RG, Jao EE, Bennett F, McCormick J, Wang H, Pike RE, Bogen SL, Liu Y-T, Arasappan A et al.): Novel peptides as NS3-serine protease inhibitors of hepatitis C virus. WO-00208256 (2002).
52. Schering Corp (Arasappan A, Parekh T, Njorge FG, Girijavallabhan VM, Ganguily AK): Novel imidazolidinones as NS3-serine protease inhibitors of hepatitis C virus. WO-00208198 (2002).
53. Schering Corp (Venkatraman S, Chen KX, Arasappan A, Njoroge FG, Girijavallabhan V, Chan T-Y, Mckittrick BA, Prongay AJ, Madison VS): Macrocyclic NS3-serine protease inhibitors of HCV comprising alkyl and aryl alanine P2 moieties. WO-00181325 (2001).
54. Schering Corp (Chen KX, Arasappan A, Venkatraman S, Parekh TN, Gu H, Njoroge FG, Girijavallabhan VM, Ganguly A, Saksena A, Jao E, Yao NH, Prongay AJ, Madison VS, Vibulbhan B): Macrocylic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties. WO-00177113 (2001).
55. Dupont Pharmaceuticals Company (Zhang Xiaojun, Han W): Inhibitors of hepatitis C virus NS3 protease. WO-00164678 (2001).
56. Istituto di Ricerche di Biologia Molecolare (Fattori D, Pessi A, Ingallinella P, Bianchi E): HSV NS3 protease inhibitors. WO-00132691 (2001). The reported compounds weakly inhibited NS3 but, unlike other inhibitors, these inhibitors project further into the prime site.
57. Novirio Pharmaceuticals/Università Degli Studi di Cagliari (Sommadossi J-P, Lacolla P): Methods and compositions for treating flaviviruses and pestiviruses. WO-00192282 (2001).
58. Novirio Pharmaceuticals/Universita Degli Studi di Cagliari (Sommadossi J-P, Lacolla P): Methods and compositions for treating hepatitis C virus. WO-00190121 (2001).
59. F Hoffmann-La Roche Ltd (Devos R, Dymock BW, Hobbs CJ, Jiang WR, Martin JA, Merrett JH, Najera I, Shimma N, Tsukuda T): Nucleoside derivatives as inhibitors of subgenomic hepatitis C viral replication. WO-00218404 (2002).
60. Japan Tobacco (Hashimoto H, Mizutani K, Yoshida A): Fused ring compounds and use thereof as drugs. WO-00147883 (2001).
61. SmithKline Beecham (Dhanak D, Kaura AC, Shaw A): Novel anti-infectives. WO-00185172 (2001).
62. SmithKline Beecham Corp (Dhanak D, Carr T): Novel anti-infectives. WO-00185720 (2001).
63. Tularik Inc (Jaen JC, Piper DE, Powers JP, Walker NPC, Li Y): NS5B HCV polymerase inhibitors. WO-00177091 (2001). These compounds are irreversible inhibitors of NS5B due to covalent linkage to a crucial Cys residue.
64. Boehringer Ingelheim (Beaulieu PL, Fazel G, Gillard J, Kukolj G, Austel V): Viral polymerase inhibitors. WO-00204425 (2002).
65. Shionogi & Co (Fujishita T, Abe K): Compounds having anti-hepatitis C virus effect. WO-00220497 (2002).
66. Schering Corp (Ganguly AK, McCormick J, Lovey R, Bennett F, Saskena AK, Girijavallabhan VM): Ribavirin-interferon-α combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection. WO-00181359 (2001).
67. ICN Pharmaceuticals Inc (Tam R, Ramasamy K, Hong L, Lau J): Nucleoside analogs with carboxamidine modified monocyclic base. WO-00160379 (2001). Increase in Th1 cytokines is highly variable among patients, and a positive effect was only seen in a few samples.
68. Bristol-Myers Squibb (Iwanowicz EJ, Watterson SH, Dhar TG, Pitts WJ, Gu HH): Heterocycles that are inhibitors of IMPDH enzyme. WO-00181340 (2001).
69. F Hoffmann-La Roche AG (Broadhurst MJ, Hill CH, Hurst DN, Jones PS, Kay PB, Kilford IR, McKinnell RM): Oxamides as IMPDH inhibitors. EP-01127883 (2001).
70. Novirio Pharmaceuticals Limited (Bryant ML, Gosselin G, Imbach J-L): 3′-prodrugs of 2′-deoxy-β-L-nucleosides. WO-00196353 (2001).
71. Pharmasset Ltd (Watanabe KA, Pai BS): 3′- or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections. WO-00179246 (2001).
72. Commonwealth Scientific and Industrial Research Organisation (Marcuccio SM, Jarvis KE): Antiviral agents. WO-00194348 (2001).
73. Bayer Aktiengesellschaft (Niewohner U, Stoltefuss J, Goldman S, Kramer T, Schlemmer K-H, Keldenich J, Paessens A, Graef E, Weber O, Deres K): Medicaments against viral diseases. WO-00168647 (2001).
74. Scriptgen Pharmaceuticals Inc (Arenas JE, Cload ST, Fleming ES, Xiang YB): Triazine antiviral compounds. US-06335339 (2001).
75. University of Georgetown (Casey JL, Korba BE, Cote PJ, Gerin JL, Tennant B, Chu CK): Method of treating hepatitis delta viral infection. WO-00172294 (2001). The patent claims that some nucleoside analogs have activity against HDV.
76. Novirio Pharmaceuticals Limited (Sommadossi J-P, Bryant ML): Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides. WO-00191737 (2001).
77. University College Cardiff Consultants Limited (McGuigan C, Balzarini J, De Clercq E): Anti-viral pyrimidine nucleoside analogues. WO-00185749 (2001).
78. Pharmacia & Upjohn Company (Thaisrivongs S, Turner SR, Thorarensen A): Oxazinoquinolones useful for the treatment of viral infections. WO-00204462 (2002). This reports the first in a series of non-nucleoside DNA polymerase inhibitors of HCMV.
79. Pharmacia & Upjohn Company (Anderson DJ, Beauchamp TJ, Bundy GL, Ciske FL, Farrell JR, Graber DR, Genin MJ, Judge TM, Moon MW, Schnute ME, Strohbach JW et al.): Heterocycle carboxamides as antiviral agents. WO-00204445 (2002).
80. Pharmacia & Upjohn (Vaillancourt VA, Staley S, Huang A, Nugent RA, Chen K, Nair SK, Nieman JA, Strohbach JW): Pyrroloquinolones as antiviral agents. WO-00202558 (2002).
81. Pharmacia & Upjohn Company (Schnute ME): Heterocycle carboxamides as antiviral agents. WO-00204422 (2001).
82. Pharmacia & Upjohn Company (Vaillancourt VA): 4-Hydroxy-1,8-napthyridine-3-carboxamides as antiviral agents. WO-00170742 (2001).
83. Pharmacia & Upjohn Company (Vaillancourt VA, Thorarensen A): 4-Oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents. WO-00174816 (2001).
84. Pharmacia & Upjohn Company (Bundy GL, Ciske FL, Genin MJ, Heasley SE, Larsen SD, Lee BH, May PD, Palmer JR, Schnute ME, Vaillancourt VA, Thorarensen A et al.): Heterocycle carboxamides as antiviral agents. WO-00204444 (2001).
85. Pharmacia & Upjohn Company (Vaillancourt VA, Larsen SD, Nair SK): 4-Oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents. WO-00170706 (2001).
86. Pharmacia & Upjohn Company (Vaillancourt VA, Larsen SD, Nair SK): 4-Hydroxycinnoline-3-carboxyamides as antiviral agents. WO-00181318 (2001).
87. Boehringer Ingelheim Ltd (Crute JJ, Faucher A-M, Grygon C, Hargrave KD, Simoneau B, Thavonekham B): Antiherpes virus compounds and methods for their preparation and use. US-06288091 (2001).
88. Boehringer Ingelheim Ltd (Simoneau B, Liuzzi M, Mentrup A): HSV primase inhibitors. US-06323202 (2001).
89. SmithKline Beecham Corp (Burton GO, Keenan RM, Knight SD, Ridgers LH): Novel anti-infectives. US-20010007877 (2001).
90. Janssen Pharmaceutica NV (Janssens FE, Meersman KPM-J, Sommen FM, Guillemont JEG, Lacrampe JFA, Andries KJLM): Respiratory syncytial virus replication inhibitors. WO-00100611 (2001). This is the first in a series of patents that claim activity against RSV.
91. Janssen Pharmaceutica NV (Janssens FE, Meersman KPM-J, Sommen FM, Andries KJLM): Respiratory syncytial virus replication inhibitors. WO-00100612 (2001).
92. Janssen Pharmaceutica NV (Janssens FE, Lacrampe JFA, Guillemont JEG, Venet MG, Andries KJLM): Respiratory syncytial virus replication inhibitors. WO-00100615 (2001).
93. Janssen Pharmaceutica NV (Saha AK, End DW, De Corte BLD, Breslin HJ, Liu L): Triazoles of farnesyl transferase inhibitors. WO-00136395 (2001).
94. Bristol-Myers Squibb Co (Yu K-L, Civiello R, Combrink KD, Gulgeze HB, Sin N, Wang X, Meanwell NA, Venables BL): Imidazo-pyridine and -pyrimidine derivatives which are inhibitors of respiratory syncytial virus infection. WO-00195910 (2001).
95. Bristol-Myers Squibb Co (Yu K-L, Civiell R, Combrink KD, Gulgeze HB, Pearce BC, Wang X, Meanwell NA, Zhang Y): Benzimidazolone antiviral agents useful for treating RSV infection. WO-00226228 (2001).
96. Agouron Pharmaceuticals Inc (Dragovich PS, Prins TJ, Zhou R, Johnson TO): Preparation of pyridonylacetamide peptide analogs as antipicornaviral agents. WO-00140189 (2001).
97. Roche AG (Hurst DN, Jones PS, Parkes KE, Parratt MJ, Wilson FX): Benzodiazepenes as inhibitors of HPV E1 helicase. WO-00200632 (2002).
98. Origenix Technologies Inc (Iyer R, Jin Y, Zhou W, Roland A): HPV-specific short-mers. WO-00177294 (2001).
99. Polydex Pharmaceuticals (Usher T, Anderson RA, Zaneveld LJD): Cellulose sulfate and other sulfated polysaccharides to prevent and treat papilloma virus infection and other infections. WO-00202189 (2001).